1. Academic Validation
  2. Recent advances in the discovery of potent and selective HDAC6 inhibitors

Recent advances in the discovery of potent and selective HDAC6 inhibitors

  • Eur J Med Chem. 2018 Jan 1:143:1406-1418. doi: 10.1016/j.ejmech.2017.10.040.
Xiu-Xiu Wang 1 Ren-Zhong Wan 2 Zhao-Peng Liu 3
Affiliations

Affiliations

  • 1 Institute of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012, PR China.
  • 2 College of Animal Science & Veterinary Medicine, Shandong Agricultural University, 61 Daizong Street, Taian 271018, PR China. Electronic address: wrzh@sdau.edu.cn.
  • 3 Institute of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012, PR China. Electronic address: liuzhaop@sdu.edu.cn.
Abstract

Histone deacetylase HDAC6, a member of the class IIb HDAC family, is unique among HDAC Enzymes in having two active catalytic domains, and has unique physiological function. In addition to the modification of histone, HDAC6 targets specific substrates including α-tubulin and HSP90, and are involved in protein trafficking and degradation, cell shape and migration. Selective HDAC6 inhibitors are an emerging class of pharmaceuticals due to the involvement of HDAC6 in different pathways related to neurodegenerative diseases, Cancer, and immunology. Therefore, extensive investigations have been made in the discovery of selective HDAC6 inhibitors. Based on their different zinc binding groups (ZBGs), in this review, HDAC6 inhibitors are grouped as hydroxamic acids, a sulfur containing ZBG based derivatives and Other ZBG-derived compounds, and their enzymatic inhibitory activity, selectivity and Other biological activities are introduced and summarized.

Keywords

HDAC6; HDAC6 inhibitors; Hydroxamic acids; Sulfur containing ZBGs; Zinc binding groups.

Figures